Company: CRNX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-029050
Chunk: 318

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 7
Chunk 318
---
 135,447

    85,279

    50,168

    Total research and development expenses
     
    $
    240,156

    $
    168,527

    $
    71,629

The following table summarizes our research and development expenses by program for the years ended December 31, 2024 and 2023 (in thousands):

78

    Year ended December 31,

    Dollar

    2024

    2023

    Change

    Paltusotine
     
    $
    48,536

    $
    46,772

    $
    1,764

    Atumelnant

    23,980

    13,118

    10,862

    CRN04777

    626

    7,754

    (7,128
    )

    Early research and development programs

    25,445

    12,667

    12,778

    Payroll and benefits

    78,817

    53,446

    25,371

    Stock-based compensation

    40,667

    22,633

    18,034

    Other

    22,085

    12,137

    9,948

      Total research and development expenses
     
    $
    240,156

    $
    168,527

    $
    71,629

Research and development expenses for paltusotine were $48.5 million and $46.8 million for the years ended December 31, 2024 and 2023, respectively. The change was primarily due to increased spending on outside services of $3.9 million, offset by decreased manufacturing and development activities of $2.2 million.

Research and development expenses for our atumelnant clinical studies were $24.0 million and $13.1 million for the years ended December 31, 2024 and 2023, respectively. The change was primarily due to increased spending on development activities of $9.4 million as the program progressed into clinical trials in patients.

Research and development expenses for our CRN04777 clinical studies were $0.6 million and $7.8 million for the years ended December 31, 2024 and 2023, respectively. The change was primarily due to decreased spending on manufacturing and development activities of $2.